Frequently Asked Questions
The market is segmented based on , By Drugs (Anti-Inflammatory, Anti-Infective, Anti-Glaucoma, Anti-Allergy, Anti-Vascular Endothelial Growth Factor, and Others), Disease (Dry Eye, Allergies, Glaucoma, Eye Infection, Infection, Retinal Disorders, Uveitis, and Others), Dosage Form (Gels, Eye Solutions and Suspensions, Capsules and Tablets, Eye Drops, and Ointments), Route of Administration (Topical, Local Ocular, and Systemic), Product Type (Prescription Drugs and OTC), and Product (Branded Drugs and Generic Drugs), End-Users (Hospitals, Specialty Clinics, and Others), Distribution Channel (Direct and Indirect) – Industry Trends and Forecast to 2031.
.
The Global Ophthalmic Drugs Market size was valued at USD 30.37 USD Million in 2023.
The Global Ophthalmic Drugs Market is projected to grow at a CAGR of 7.3% during the forecast period of 2024 to 2031.
The major players operating in the market include Akorn Operating Company LLC. (U.S.), Johnson & Johnson Services, Inc.(U.S.), Mitotech Ltd (Germany), AbbVie Inc. (U.S.), Santen Pharmaceutical Co. Ltd. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Bausch Health Companies Inc. (Canada.), AERIE PHARMACEUTICALS, INC. (U.S.), Novartis AG (Switzerland), Merck & Co. Inc. (U.S.), Bayer AG (Germany), and F. Hoffmann-La Roche Ltd (Switzerland).
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
